1-((3s,4r)-3-((2-((1 ethyl 1h pyrazol 4 yl)amino)-7h pyrrolo[2,3 d]pyrimidin 4 yl)oxy)-4 fluoropiperidin 1 yl)prop 2 in 1 one tartrate salt, crystalline form thereof and method for its preparation

Abstract

This disclosure relates to a tartrate salt of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, a crystalline form thereof, and a method for its preparation. The tartrate salt and crystalline form have low hygroscopicity compared to the free base and improved stability and solubility, making them suitable for pharmaceutical use. Furthermore, the method for preparing the tartrate salt and crystalline form according to this disclosure has the advantage of enabling mass production and improving the safety of the preparation procedure by using safer materials than the reactants used in conventional preparation methods.